Drug Patents owned by Mylan Speciality Lp
1. List of Astepro drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9919050 | MYLAN SPECIALITY LP | Compositions comprising azelastine |
Nov, 2025
(2 years from now) | |
| US8518919 | MYLAN SPECIALITY LP | Compositions comprising azelastine and methods of use thereof |
Nov, 2025
(2 years from now) | |
| US8071073 | MYLAN SPECIALITY LP | Compositions comprising azelastine and methods of use thereof |
Jun, 2028
(5 years from now) | |
Drugs and Companies using AZELASTINE HYDROCHLORIDE ingredient
Market Authorisation Date: 15 October, 2008
Treatment: Treatment of allergic rhinitis, including seasonal and perennial allergic rhinitis
Dosage: SPRAY, METERED;NASAL
ASTEPRO family patents
9
United States
4
European Union
3
Spain
3
Denmark
3
Poland
3
Korea, Republic of
3
Portugal
3
Australia
3
Lithuania
3
Slovenia
2
Japan
2
Israel
2
Mexico
2
Hungary
1
Hong Kong
1
Turkey
1
RS
1
China
1
Brazil
1
Canada
1
New Zealand
1
Croatia
1
Cyprus
1
South Africa
2. List of Dymista drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9901585 | MYLAN SPECIALITY LP | Combination of azelastine and fluticasone for nasal administration |
Jun, 2023
(11 days from now) | |
| US9259428 | MYLAN SPECIALITY LP | Combination of azelastine and fluticasone for nasal administration |
Jun, 2023
(11 days from now) | |
| US8163723 | MYLAN SPECIALITY LP | Combination of azelastine and steroids |
Aug, 2023
(2 months from now) | |
|
US9259428 (Pediatric) | MYLAN SPECIALITY LP | Combination of azelastine and fluticasone for nasal administration |
Dec, 2023
(6 months from now) | |
|
US8163723 (Pediatric) | MYLAN SPECIALITY LP | Combination of azelastine and steroids |
Feb, 2024
(8 months from now) | |
| US8168620 | MYLAN SPECIALITY LP | Combination of azelastine and steroids |
Feb, 2026
(2 years from now) | |
|
US8168620 (Pediatric) | MYLAN SPECIALITY LP | Combination of azelastine and steroids |
Aug, 2026
(3 years from now) | |
Drugs and Companies using AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE ingredient
Market Authorisation Date: 01 May, 2012
Treatment: Treatment of seasonal allergic rhinitis; Treatment of allergic rhinitis, including seasonal allergic rhinitis; Allergic rhinitis; Treatment of symptoms of seasonal allergic rhinitis; Relief of symptom...
Dosage: SPRAY, METERED;NASAL
DYMISTA family patents
10
United States
4
Brazil
3
Spain
3
Denmark
3
Canada
3
Korea, Republic of
3
Cyprus
3
Israel
3
Portugal
3
Australia
3
Slovenia
3
European Union
2
United Kingdom
2
New Zealand
2
Hungary
1
Austria
1
Poland
1
Russia
1
Germany
1
China
1
Morocco
1
Georgia
1
Mexico
1
Costa Rica
1
South Africa
1
Luxembourg
1
Tunisia
3. List of Edluar drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9597281 | MYLAN SPECIALITY LP | Pharmaceutical formulations useful in the treatment of insomnia |
Apr, 2027
(3 years from now) | |
| US9265720 | MYLAN SPECIALITY LP | Pharmaceutical formulations useful in the treatment of insomnia |
Feb, 2031
(7 years from now) | |
Drugs and Companies using ZOLPIDEM TARTRATE ingredient
Market Authorisation Date: 13 March, 2009
Treatment: Method of treating insomnia characterized by difficulty with sleep onset
Dosage: TABLET;SUBLINGUAL
EDLUAR family patents
5
United States
2
Poland
2
United Kingdom
2
Cyprus
2
Portugal
2
Lithuania
2
Denmark
2
Slovenia
2
European Union
1
Spain
1
Japan
1
Hungary
4. List of Elestrin drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7198801 | MYLAN SPECIALITY LP | Formulations for transdermal or transmucosal application |
Jun, 2022
(11 months ago) | |
Drugs and Companies using ESTRADIOL ingredient
Market Authorisation Date: 15 December, 2006
Treatment: NA
Dosage: GEL, METERED;TRANSDERMAL
ELESTRIN family patents
18
United States
10
European Union
4
Austria
4
Japan
4
Australia
3
Spain
3
Germany
3
Canada
3
New Zealand
3
Mexico
2
China
2
Brazil
2
Korea, Republic of
2
South Africa
1
Hong Kong
1
Denmark
1
Poland
1
Argentina
1
Israel
1
Portugal
5. List of Epi E Z Pen Jr drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7449012 | MYLAN SPECIALITY LP | Automatic injector |
Sep, 2025
(2 years from now) | |
| US8048035 | MYLAN SPECIALITY LP | Automatic injector with needle cover |
Sep, 2025
(2 years from now) | |
| US7794432 | MYLAN SPECIALITY LP | Automatic injector with kickback attenuation |
Sep, 2025
(2 years from now) | |
| US9586010 | MYLAN SPECIALITY LP | Automatic injector with needle cover |
Sep, 2025
(2 years from now) | |
| US8870827 | MYLAN SPECIALITY LP | Automatic injector |
Sep, 2025
(2 years from now) | |
Drugs and Companies using EPINEPHRINE ingredient
Market Authorisation Date: 22 December, 1987
Treatment: NA
Dosage: INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS
EPI E Z PEN JR family patents
15
United States
4
Poland
4
Spain
4
Slovenia
4
Denmark
4
European Union
3
Cyprus
3
Portugal
3
Australia
3
Hungary
2
Canada
2
Japan
1
Korea, Republic of
1
China
1
Israel
1
Singapore
1
Taiwan
1
Mexico
6. List of Rowasa drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7645801 | MYLAN SPECIALITY LP | Reduced irritant enema for treatment of inflammatory bowel disease (IBD) |
Jul, 2027
(4 years from now) | |
Drugs and Companies using MESALAMINE ingredient
Market Authorisation Date: 24 December, 1987
Treatment: NA
Dosage: ENEMA;RECTAL
ROWASA family patents
4
United States
1
New Zealand
1
Spain
1
Canada
1
Australia
1
Denmark
1
European Union
7. List of Tobi Podhaler drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9421166 | MYLAN SPECIALITY LP | Pulmonary delivery of aminoglycoside |
Dec, 2022
(5 months ago) | |
| US7368102 | MYLAN SPECIALITY LP | Pulmonary delivery of aminoglycosides |
Dec, 2022
(5 months ago) | |
| US8715623 | MYLAN SPECIALITY LP | Pulmonary delivery of aminoglycoside |
Dec, 2022
(5 months ago) | |
| US7516741 | MYLAN SPECIALITY LP | Aerosolization apparatus with feedback mechanism |
Jan, 2024
(7 months from now) | |
| USRE47526 | MYLAN SPECIALITY LP | Aerosolization apparatus with air inlet shield |
Apr, 2024
(10 months from now) | |
| US8069851 | MYLAN SPECIALITY LP | Aeorosolization apparatus with air inlet shield |
Sep, 2024
(1 year, 3 months from now) | |
| US11484671 | MYLAN SPECIALITY LP | Aerosolization apparatus with capsule puncture alignment guide |
Nov, 2024
(1 year, 5 months from now) | |
| US8664187 | MYLAN SPECIALITY LP | Methods of treatment of endobronchial infections |
Jun, 2025
(2 years from now) | |
| US7559325 | MYLAN SPECIALITY LP | Aerosolization apparatus with air inlet shield |
Oct, 2025
(2 years from now) | |
| US8869794 | MYLAN SPECIALITY LP | Aerosolization apparatus with capsule puncturing member |
Sep, 2028
(5 years from now) | |
| US10207066 | MYLAN SPECIALITY LP | Aerosolization apparatus with capsule puncture alignment guide |
Nov, 2030
(7 years from now) | |
Drugs and Companies using TOBRAMYCIN ingredient
Market Authorisation Date: 22 March, 2013
Treatment: Treatment of cystic fibrosis patients with pseudomonas aeruginosa
Dosage: POWDER;INHALATION
TOBI PODHALER family patents
24
United States
7
Japan
5
Korea, Republic of
4
Spain
4
Denmark
4
Canada
4
Cyprus
4
Mexico
4
Australia
4
Slovenia
4
European Union
3
Poland
3
Portugal
2
Austria
1
China
1
Russia
1
Brazil
1
Singapore
1
Morocco
1
Norway
1
New Zealand
1
Croatia
1
Israel
1
Taiwan
1
Ecuador
1
South Africa
1
Tunisia
1
Hungary
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic